Presented at the Meeting of the Southern Section of the American Laryngological, Rhinological and Otological Society, Inc., New Orleans, Louisiana, January 17, 1998.
In Vivo Interaction of Cis-platinum and Fosfomycin on Squamous Cell Carcinoma†
Article first published online: 2 JAN 2009
Copyright © 2000 The Triological Society
Volume 110, Issue 7, pages 1222–1224, 2000
How to Cite
Tandy, J. R., Tandy, R. D., Farris, P. and Truelson, J. M. (2000), In Vivo Interaction of Cis-platinum and Fosfomycin on Squamous Cell Carcinoma. The Laryngoscope, 110: 1222–1224. doi: 10.1097/00005537-200007000-00029
- Issue published online: 2 JAN 2009
- Article first published online: 2 JAN 2009
- Manuscript Accepted: 1 MAR 2000
- squamous cell carcinoma.
Objectives/Hypothesis Cis-platinum is the most frequently used chemotherapeutic agent for the treatment of head and neck squamous cell carcinoma (SCCA). Ototoxicity and nephrotoxicity continue to be the primary dose-limiting toxicities encountered. Fosfomycin, a broad-spectrum antibiotic, has been previously shown to be both otoprotective and nephroprotective against cis-platinum toxicity. Previous in vitro work demonstrated that fosfomycin does not inhibit the tumoricidal actions of cis-platinum. This study tests whether fosfomycin inhibits cis-platinum in vivo.
Methods An SCCA cell line was grown in vivo in four groups of nude mice, which then received no treatment, standard-dose cis-platinum, high-dose cis-platinum, or high-dose cis-platinum with fosfomycin.
Results Fosfomycin did not inhibit the tumoricidal activity of cis-platinum. Mice treated with fosfomycin also had longer survival, which is probably due to lessening of immediate cis-platinum systemic toxicity.
Conclusion This study shows that fosfomycin in combination with cis-platinum may be useful in treating advanced, and possibly relatively chemoresistant, SCCA of the head and neck.